Neumora Therapeutics, Inc. (NMRA)

9.42 -0.39 (-3.98%) 收市：04:00PM EDT

Neumora Therapeutics, Inc.

490 Arsenal Way
Suite 200
Watertown, MA 02472
United States
857 760 0900
https://www.neumoratx.com

版塊: Healthcare
行業: Biotechnology
全職員工: 124

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Paul L. Berns	Co-Founder & Executive Chairman	1.65M	無	1967
Mr. Henry O. Gosebruch	President, CEO & Director	3.33M	無	1973
Mr. Jason G. Duncan	Chief Legal Officer	315k	無	1974
Mr. Robert Lenz M.D., Ph.D.	Head of Research & Development	770.29k	無	1971
Ms. Carol Suh	Co-Founder & COO	無	無	1990
Dr. Robert Michael Poole FACP, M.D.	Co-Founder & Advisor	無	無	1958
Dr. Joshua Pinto Ph.D.	Chief Financial Officer	876.64k	無	1985
Mr. Michael Lee Milligan	Principal Accounting Officer	無	無	無
Dr. Rajesh Manchanda Ph.D.	Chief Technical Operations Officer	無	無	1966
Mr. Nicholas Brandon Ph.D.	Chief Scientific Officer	無	無	1974

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

公司管治

截至 無 止，Neumora Therapeutics, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。